All In Biotech

Drug Trial Radar · NCT06973720

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Multiple Dose Regimens of Once-Weekly Switching to Once-Monthly MET097 in Participants With Obesity or Overweight (VESPER-3)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 268 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

268

Actual

Start

Apr 7, 2025

Primary completion

Dec 16, 2025

Study completion Oct 19, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.

Conditions

  • Obesity
  • Overweight or Obesity

Interventions

  • MET097Drug

    For subcutaneous administration.

  • PlaceboDrug

    Sterile 0.9% (w/v) saline for subcutaneous administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in body weight at Week 28Time frame: Baseline (Week 0) through Week 28 (Day 197)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Research Centers of America

    Hollywood, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • CenExel iResearch, LLC

    Decatur, Georgia

  • CenExel iResearch, LLC

    Savannah, Georgia

  • Hassman Research Institute

    Marlton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.